{"id":509974,"date":"2021-07-06T16:33:22","date_gmt":"2021-07-06T20:33:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/"},"modified":"2021-07-06T16:33:22","modified_gmt":"2021-07-06T20:33:22","slug":"codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/","title":{"rendered":"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles"},"content":{"rendered":"<h2>\n\u2013 Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company \u2013<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., July  06, 2021  (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Benny Sorensen, M.D., Ph.D. resigned from his position as a Senior Vice President of Strategic Projects to become CEO of a privately held biotech company, Hemab Therapeutics, focused on rare bleeding and thrombosis disorders. Dr. Sorensen has been appointed to Codiak\u2019s Scientific Advisory Board and will serve in a consultant role for Codiak through planned clinical data readouts later this year for both of the company\u2019s lead programs, exoSTING\u2122 and exoIL-12\u2122.\u00a0 \u00a0<\/p>\n<p align=\"left\">\u201cBenny has been an ardent champion of the potential of exosome-based therapeutics since he joined Codiak in 2016 and has skillfully led our clinical development efforts as we have endeavored to break new ground with a novel modality,\u201d said Douglas E. Williams, Ph.D., CEO, Codiak. \u201cWe are extremely grateful for Benny\u2019s many contributions to Codiak, and we are glad that he will remain involved with the company. We wish him every success as he takes the helm of a start-up hemostasis and thrombosis company, which is an ideal fit with Benny\u2019s background and expertise. Benny has built a talented team at Codiak and the addition of Jennifer Wheler, M.D. as Chief Medical Officer in recent months has positioned the company well as we work to advance our novel programs and further expand our clinical pipeline.\u201d<\/p>\n<p align=\"left\">Most recently, Dr. Sorensen has held the role of Senior Vice President, Strategic Projects at Codiak and before that, SVP, Head of Clinical Development. Dr. Sorensen was instrumental in the design and initiation of Codiak\u2019s first two clinical programs \u2013 exoIL-12 and exoSTING \u2013 which were the first ever engineered exosome-based therapeutic candidates to enter the clinic. Preliminary topline data for the ongoing Phase 1\/2 trial of exoSTING are expected in Q3 of this year and initial data from the exoIL-12 Phase 1 program in cutaneous T cell lymphoma patients are anticipated by year end.<\/p>\n<p align=\"left\">Dr. Sorensen stated, \u201cI am honored to be joining Codiak\u2019s Scientific Advisory Board, and to serve along with some of the world\u2019s thought leaders in oncology and immunology. I believe strongly in the potential of Codiak\u2019s science and its engEx\u2122 Platform that\u2019s been built and eagerly await our first patient data sets in trials for exoSTING and exoIL-12, expected later this year. I look forward to continuing to work closely with the company in my new advisory roles.\u201d<\/p>\n<p align=\"left\">\n        <strong>About Codiak BioSciences <\/strong><br \/>\n        <br \/>Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements concerning the development and therapeutic potential of the Company\u2019s engEx Platform, engEx product candidates and engineered exosomes generally, including future development plans, data releases and timing with respect thereto. Any forward-looking statements in this press release are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled \u201cRisk Factors\u201d in Codiak\u2019s Annual Report on Form\u00a010-K\u00a0for the year ended December\u00a031, 2020, and in subsequent filings with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in Codiak\u2019s subsequent filings with the Securities and Exchange Commission. All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8eb84be1-24f1-45ee-be7f-462893123a97\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contact:\r\nChristopher Taylor\r\nVP, Investor Relations and Corporate Communications\r\nT: 617-949-4220\r\nE: investor@codiakbio.com\r\n\r\nMedia Contact:\r\nLindy Devereux\r\nScient PR\r\nT: 646-515-5730\r\nE: media@codiakbio.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company \u2013 CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Benny Sorensen, M.D., Ph.D. resigned from his position as a Senior Vice President of Strategic Projects to become CEO of a privately held biotech company, Hemab Therapeutics, focused on rare bleeding and thrombosis disorders. Dr. Sorensen has been appointed to Codiak\u2019s Scientific Advisory Board and will serve in a consultant role for Codiak through planned clinical data readouts later this year for both of the company\u2019s lead programs, exoSTING\u2122 and exoIL-12\u2122.\u00a0 \u00a0 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-509974","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company \u2013 CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Benny Sorensen, M.D., Ph.D. resigned from his position as a Senior Vice President of Strategic Projects to become CEO of a privately held biotech company, Hemab Therapeutics, focused on rare bleeding and thrombosis disorders. Dr. Sorensen has been appointed to Codiak\u2019s Scientific Advisory Board and will serve in a consultant role for Codiak through planned clinical data readouts later this year for both of the company\u2019s lead programs, exoSTING\u2122 and exoIL-12\u2122.\u00a0 \u00a0 &hellip; Continue reading &quot;Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-06T20:33:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles\",\"datePublished\":\"2021-07-06T20:33:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/\"},\"wordCount\":770,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/\",\"name\":\"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI=\",\"datePublished\":\"2021-07-06T20:33:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/","og_locale":"en_US","og_type":"article","og_title":"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles - Market Newsdesk","og_description":"\u2013 Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company \u2013 CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Benny Sorensen, M.D., Ph.D. resigned from his position as a Senior Vice President of Strategic Projects to become CEO of a privately held biotech company, Hemab Therapeutics, focused on rare bleeding and thrombosis disorders. Dr. Sorensen has been appointed to Codiak\u2019s Scientific Advisory Board and will serve in a consultant role for Codiak through planned clinical data readouts later this year for both of the company\u2019s lead programs, exoSTING\u2122 and exoIL-12\u2122.\u00a0 \u00a0 &hellip; Continue reading \"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-06T20:33:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles","datePublished":"2021-07-06T20:33:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/"},"wordCount":770,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/","name":"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI=","datePublished":"2021-07-06T20:33:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTk3MiM0Mjg0NzYzIzIxNTcwMDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-biosciences-announces-the-transition-of-benny-sorensen-m-d-ph-d-to-scientific-advisory-board-member-and-clinical-consultant-roles\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=509974"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509974\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=509974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=509974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=509974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}